Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects
- 3 August 2007
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (10) , 2153-2155
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjectsBlood, 2006
- Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to ClopidogrelArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Biological effects of aspirin and clopidogrel in a randomized cross‐over study in 96 healthy volunteersJournal of Thrombosis and Haemostasis, 2006
- Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial InfarctionCirculation, 2004
- “Are We There Yet?”: Deciding When One Has Demonstrated Specific Genetic Causation in Complex Diseases and Quantitative TraitsThe American Journal of Human Genetics, 2003
- Genetic associations in large versus small studies: an empirical assessmentThe Lancet, 2003
- Replication validity of genetic association studiesNature Genetics, 2001
- Identification of the platelet ADP receptor targeted by antithrombotic drugsNature, 2001